[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2888234T - Haptenos de aripiprazol e seu uso em imunoensaios - Google Patents

Haptenos de aripiprazol e seu uso em imunoensaios

Info

Publication number
PT2888234T
PT2888234T PT137537734T PT13753773T PT2888234T PT 2888234 T PT2888234 T PT 2888234T PT 137537734 T PT137537734 T PT 137537734T PT 13753773 T PT13753773 T PT 13753773T PT 2888234 T PT2888234 T PT 2888234T
Authority
PT
Portugal
Prior art keywords
aripiprazole
haptens
immunoassays
Prior art date
Application number
PT137537734T
Other languages
English (en)
Inventor
Salter Rhys
Hryhorenko Eric
R Decory Thomas
M Remmerie Bart
Sankaran Banumathi
Lin Ronghui
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT2888234T publication Critical patent/PT2888234T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT137537734T 2012-08-21 2013-08-20 Haptenos de aripiprazol e seu uso em imunoensaios PT2888234T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691450P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
PT2888234T true PT2888234T (pt) 2018-02-22

Family

ID=49081006

Family Applications (2)

Application Number Title Priority Date Filing Date
PT137537734T PT2888234T (pt) 2012-08-21 2013-08-20 Haptenos de aripiprazol e seu uso em imunoensaios
PT172047342T PT3321254T (pt) 2012-08-21 2013-08-20 Haptenos de aripiprazol e seu uso em imunoensaios

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT172047342T PT3321254T (pt) 2012-08-21 2013-08-20 Haptenos de aripiprazol e seu uso em imunoensaios

Country Status (11)

Country Link
US (3) US9504682B2 (pt)
EP (2) EP3321254B1 (pt)
JP (1) JP6131414B2 (pt)
CN (3) CN104822660A (pt)
AU (2) AU2013306015B2 (pt)
CA (1) CA2882449C (pt)
ES (2) ES2652641T3 (pt)
HK (2) HK1211932A1 (pt)
PL (2) PL3321254T3 (pt)
PT (2) PT2888234T (pt)
WO (1) WO2014031584A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
JP6339569B2 (ja) 2012-08-21 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンへの抗体及びその使用
EP3663316A1 (en) 2012-08-21 2020-06-10 Janssen Pharmaceutica NV Antibodies to aripiprazole and use thereof
EP3333195B1 (en) 2012-08-21 2020-08-05 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
WO2014031665A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
WO2014031635A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to aripiprazole haptens and use thereof
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
AU2016370853A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to quetiapine and use thereof
JP6949025B2 (ja) 2015-12-17 2021-10-13 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンに対する抗体及びその使用
CN108196055B (zh) * 2017-11-28 2020-07-07 泰州泽成生物技术有限公司 磁微粒化学发光法测定地高辛含量的试剂盒及其检测方法
CN110922357A (zh) * 2019-10-30 2020-03-27 杭州博拓生物科技股份有限公司 一种阿立哌唑人工抗原及其制备方法
CN115181076B (zh) * 2022-06-24 2023-03-24 北京丹大生物技术有限公司 一种用于检测阿立哌唑和脱氢阿立哌唑浓度的半抗原、抗原、细胞株、抗体、试剂和试剂盒

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH0746107B2 (ja) 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ 検定法
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
TW268005B (pt) 1992-05-29 1996-01-11 Lilly Industries Ltd
JP2960628B2 (ja) 1992-06-26 1999-10-12 イーストマン コダック カンパニー 標識サイロニンハプテン類似体を用いたイムノアッセイ
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
JPH07247271A (ja) 1994-01-21 1995-09-26 Otsuka Pharmaceut Co Ltd ３，４−ジヒドロカルボスチリル誘導体
DE69535855D1 (de) 1994-06-10 2008-11-20 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
US6139800A (en) 1997-06-23 2000-10-31 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
KR20040088519A (ko) 2002-02-22 2004-10-16 뉴 리버 파마슈티칼스, 인크. 활성 제제 전달 시스템 및 활성 제제의 보호 및 투여 방법
WO2003074566A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Rs7 antibodies
US7214673B2 (en) 2002-03-28 2007-05-08 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
WO2004014895A1 (en) 2002-08-05 2004-02-19 Eli Lilly And Company Piperazine substituted aryl benzodiazepines
EP1658277B1 (en) 2003-08-18 2012-04-04 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
ATE452882T1 (de) 2003-09-23 2010-01-15 Fermion Oy Herstellung von quetiapin
KR101255074B1 (ko) 2003-10-01 2013-04-16 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
AU2004298660B2 (en) 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CN100340543C (zh) * 2005-12-13 2007-10-03 浙江大学 氰戊菊酯半抗原化合物、合成方法及其用途
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
FR2918664B1 (fr) 2007-07-11 2009-10-02 Commissariat Energie Atomique Reactif pseudo peptidique trifonctionnel, ses utilisations et applications.
US8076160B2 (en) * 2007-09-27 2011-12-13 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
CN105481980A (zh) 2008-07-21 2016-04-13 前体生物药物股份公司 诊断抗体测定
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
WO2010033270A1 (en) 2008-09-17 2010-03-25 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
CN102245605B (zh) 2008-10-14 2016-01-27 阿斯利康(瑞典)有限公司 用于治疗细菌感染的稠合、螺环杂芳族化合物
JP2012507297A (ja) 2008-10-29 2012-03-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｅｒｂｂ４遺伝子の多型に基づく精神病及び統合失調症の治療法
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US20100203129A1 (en) 2009-01-26 2010-08-12 Egalet A/S Controlled release formulations with continuous efficacy
US8518927B2 (en) * 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
US8686009B2 (en) * 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
NZ597960A (en) 2009-07-31 2013-07-26 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
EP2485767A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Carrier linked paliperidone prodrugs
EP2343296A1 (en) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. A process for the purification of paliperidone
CN107714703A (zh) 2009-12-31 2018-02-23 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) * 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
CA2802733C (en) * 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en) 2010-07-02 2015-10-13 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine D2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
EP2741779A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
PE20151138A1 (es) 2012-08-16 2015-08-07 Janssen Pharmaceutica Nv Pirazoloes sustituidos como bloqueadores del canal de calcio tipo n
WO2014031635A1 (en) * 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to aripiprazole haptens and use thereof
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
EP3663316A1 (en) 2012-08-21 2020-06-10 Janssen Pharmaceutica NV Antibodies to aripiprazole and use thereof
EP3333195B1 (en) 2012-08-21 2020-08-05 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
WO2014031665A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to quetiapine haptens and use thereof
PT2888590T (pt) 2012-08-21 2020-09-11 Janssen Pharmaceutica Nv Anticorpos para olanzapina e utilização destes
WO2014031587A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of olanzipine
JP6131415B2 (ja) 2012-08-21 2017-05-24 ヤンセン ファーマシューティカ エヌ．ベー． イムノアッセイに使用するためのクエチアピンのハプテン
PT2888258T (pt) 2012-08-21 2019-08-21 Janssen Pharmaceutica Nv Hapteno de paliperidona
AU2013305938B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to paliperidone haptens and use thereof
EP2888277A4 (en) 2012-08-21 2016-05-18 Ortho Clinical Diagnostics Inc ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
EP3415516B1 (en) 2012-08-21 2021-12-15 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
PT2888284T (pt) 2012-08-21 2022-11-18 Janssen Pharmaceutica Nv Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
JP6339569B2 (ja) 2012-08-21 2018-06-06 ヤンセン ファーマシューティカ エヌ．ベー． リスペリドンへの抗体及びその使用
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers

Also Published As

Publication number Publication date
EP2888234B1 (en) 2017-12-06
AU2013306015A1 (en) 2015-03-05
US9795685B2 (en) 2017-10-24
CA2882449C (en) 2018-09-04
ES2652641T3 (es) 2018-02-05
WO2014031584A1 (en) 2014-02-27
US9504682B2 (en) 2016-11-29
HK1255295A1 (zh) 2019-08-16
AU2017258962A1 (en) 2017-12-21
HK1211932A1 (en) 2016-06-03
CN109970637A (zh) 2019-07-05
JP6131414B2 (ja) 2017-05-24
PL2888234T3 (pl) 2018-07-31
AU2013306015B2 (en) 2017-08-10
JP2015527363A (ja) 2015-09-17
CN109970637B (zh) 2022-04-19
AU2017258962B2 (en) 2019-08-22
CN108484496A (zh) 2018-09-04
US20180117169A1 (en) 2018-05-03
EP3321254B1 (en) 2020-08-12
CN104822660A (zh) 2015-08-05
PL3321254T3 (pl) 2021-01-11
EP2888234A1 (en) 2015-07-01
US20140163206A1 (en) 2014-06-12
CN108484496B (zh) 2022-03-22
PT3321254T (pt) 2020-10-20
ES2822914T3 (es) 2021-05-05
US20170072061A1 (en) 2017-03-16
CA2882449A1 (en) 2014-02-27
EP3321254A1 (en) 2018-05-16
US10166296B2 (en) 2019-01-01

Similar Documents

Publication Publication Date Title
HK1255295A1 (zh) 阿立哌唑半抗原及其在免疫測定中的應用
HK1211955A1 (en) Antibodies to aripiprazole haptens and use thereof
HK1211957A1 (en) Antibodies to risperidone haptens and use thereof
HK1211931A1 (en) Haptens of quetiapine for use in immunoassays
HK1211959A1 (en) Antibodies to quetiapine haptens and use thereof
HK1211857A1 (en) Antibodies to olanzapine haptens and use thereof
HK1211989A1 (en) Antibodies to aripiprazole and use thereof
HK1211956A1 (en) Antibodies to paliperidone haptens and use thereof
IL239369A0 (en) Pyrocyclic morphines and their use
HK1197187A1 (en) Anti-lrp5 antibodies and methods of use lrp5
EP2822936A4 (en) AMINOCHINOLINE DERIVATIVES AND USES THEREOF
HK1183301A1 (en) Novel quinoline derivatives and their use thereof
GB2516343B (en) Improvements in and relating to ophthalmoscopes
EP2814839A4 (en) ANTAGONISTS OF BCL-2 AND USES THEREOF IN THE INDUCTION OF APOPTOSIS
IL233882B (en) bcl–2 antagonists and their uses in induction of apoptosis